Susquehanna Fundamental Investments, LLC Kazia Therapeutics LTD Transaction History

Susquehanna Fundamental Investments, LLC

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2021 Aug 11, 2021	SELL	$9.1 - $14.71 $105,560 - $170,636	-11,600 Closed	0 $0
Q1 2021 May 17, 2021	SELL	$8.98 - $12.86 $71,840 - $102,880	-8,000 Reduced 40.82%	11,600 $144,000
Q4 2020 Feb 16, 2021	BUY	$5.61 - $13.47 $109,956 - $264,012	19,600 New	19,600 $170,000

328K

24K

Ticker KZIA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 15,111,300
Market Cap $5.14M
Description
Kazia Therapeutics Limited, an oncology-focused biotechnology company, develops anti-cancer drugs. Its lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/Akt/mTor pathway, which is developed as a potential therapy for glioblastoma. It is also developing EVT801, an investigational new drug for various...

Get notified when there are updates to the investment portfolio of Susquehanna Fundamental Investments, LLC, based on Form 13F filings with the SEC.

Stay updated on Susquehanna Fundamental Investments, LLC with notifications on news.